CR10507A - Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares - Google Patents

Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares

Info

Publication number
CR10507A
CR10507A CR10507A CR10507A CR10507A CR 10507 A CR10507 A CR 10507A CR 10507 A CR10507 A CR 10507A CR 10507 A CR10507 A CR 10507A CR 10507 A CR10507 A CR 10507A
Authority
CR
Costa Rica
Prior art keywords
dha
prevention
treatment
cardiovascular diseases
esteres
Prior art date
Application number
CR10507A
Other languages
English (en)
Inventor
Brune Frederique
Delhon Andre
Gardette Jean
Francois Patoiseau Jean
Marty Alain
Severac Etienne
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10507(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CR10507A publication Critical patent/CR10507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a los esteres del acido docsahexaenoico (DHA) con alcoholes seleccionados de entre las vitaminas o provitaminas del grupo B tales como nicotinol (B3) pantenol (B5) o con inositol (B7), o con isosorbida o monitrato de isosorbida, y en particular el docosahexaenoato de piridin-3-ilmetilo, y a su utilizacion como medicamento en el tratamiento y la prevencion de enfermedades cardiovasculares.
CR10507A 2006-06-23 2008-12-12 Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares CR10507A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0605649A FR2902659A1 (fr) 2006-06-23 2006-06-23 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
CR10507A true CR10507A (es) 2009-02-05

Family

ID=37686083

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10507A CR10507A (es) 2006-06-23 2008-12-12 Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares

Country Status (38)

Country Link
US (2) US8034377B2 (es)
EP (1) EP2034999B9 (es)
JP (1) JP5053372B2 (es)
KR (1) KR101380128B1 (es)
CN (1) CN101472590A (es)
AR (1) AR061622A1 (es)
AT (1) ATE489091T1 (es)
AU (1) AU2007262958B2 (es)
BR (1) BRPI0713725A2 (es)
CA (1) CA2655570C (es)
CL (1) CL2010001123A1 (es)
CO (1) CO6150156A2 (es)
CR (1) CR10507A (es)
DE (1) DE602007010776D1 (es)
DK (1) DK2034999T3 (es)
EC (1) ECSP099039A (es)
ES (1) ES2355611T3 (es)
FR (1) FR2902659A1 (es)
GE (1) GEP20125464B (es)
HN (1) HN2008001771A (es)
HR (1) HRP20110086T1 (es)
IL (1) IL195562A (es)
MA (1) MA30584B1 (es)
MX (1) MX2009000103A (es)
MY (1) MY145985A (es)
NO (1) NO20090334L (es)
NZ (1) NZ573454A (es)
PL (1) PL2034999T3 (es)
PT (1) PT2034999E (es)
RS (1) RS51629B (es)
RU (1) RU2451672C2 (es)
SA (1) SA07280345B1 (es)
SI (1) SI2034999T1 (es)
TN (1) TNSN08527A1 (es)
TW (1) TWI389888B (es)
UA (1) UA96156C2 (es)
WO (1) WO2007147899A2 (es)
ZA (1) ZA200900334B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334536B1 (es) * 2008-04-11 2011-01-24 Universidad Complutense De Madrid Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
ES2856723T3 (es) 2010-08-23 2021-09-28 Janssen Biotech Inc Tratamiento para enfermedades neoplásicas
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) * 2014-08-12 2016-02-18 Praj Industries Limited Process for the preparation of triglycerides of epa and dha
US10441087B2 (en) 2015-02-24 2019-10-15 Sleep Number Corporation Mattress with adjustable firmness
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
IL268804B2 (en) * 2017-02-20 2023-04-01 Univ Louisiana State Hydrogen sulfide and/or nitrite for the treatment and prevention of atrial fibrillation
CN110950881A (zh) * 2018-09-27 2020-04-03 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133049C (es) 1966-02-24
JPS5967263A (ja) 1982-10-07 1984-04-16 Terumo Corp ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja) 1982-10-08 1984-04-16 Terumo Corp 血小板凝集抑制剤
WO1984001899A1 (en) * 1982-11-16 1984-05-24 Georges Motschan New utilization of a unique vitamin or a combination of various vitamins
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
EP0823897B1 (en) 1995-05-01 2004-07-28 Scarista Limited Nicotinic acid esters and pharmaceutical compositions containing them
IL118092A0 (en) 1995-05-03 1996-09-12 Smithkline Beecham Plc Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
EP1157692B1 (en) 2000-05-22 2005-10-05 Pro Aparts - Investimentos E Consultoria Lda Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
EP1466597A1 (en) * 2003-04-07 2004-10-13 Clinigenetics Use of dha esters to control or prevent cardiovascular diseases
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
MXPA05010930A (es) 2003-04-17 2005-11-25 Boehringer Ingelheim Int Suplemento multivitaminico y mineral para mujeres embarazadas.

Also Published As

Publication number Publication date
ECSP099039A (es) 2009-02-27
CO6150156A2 (es) 2010-04-20
HN2008001771A (es) 2011-01-24
HRP20110086T1 (hr) 2011-03-31
FR2902659A1 (fr) 2007-12-28
CL2010001123A1 (es) 2011-03-25
CN101472590A (zh) 2009-07-01
JP2009544576A (ja) 2009-12-17
TW200811108A (en) 2008-03-01
NO20090334L (no) 2009-03-04
ATE489091T1 (de) 2010-12-15
GEP20125464B (en) 2012-04-10
AU2007262958A1 (en) 2007-12-27
PL2034999T3 (pl) 2011-05-31
US20110237613A1 (en) 2011-09-29
ZA200900334B (en) 2009-12-30
US20090312354A1 (en) 2009-12-17
KR20090024794A (ko) 2009-03-09
US8227479B2 (en) 2012-07-24
UA96156C2 (ru) 2011-10-10
JP5053372B2 (ja) 2012-10-17
CA2655570C (en) 2015-09-08
TWI389888B (zh) 2013-03-21
RU2451672C2 (ru) 2012-05-27
WO2007147899B1 (en) 2008-05-02
BRPI0713725A2 (pt) 2012-10-30
SI2034999T1 (sl) 2011-02-28
IL195562A (en) 2012-06-28
SA07280345B1 (ar) 2011-01-15
NZ573454A (en) 2010-10-29
DK2034999T3 (da) 2011-01-24
ES2355611T3 (es) 2011-03-29
RS51629B (en) 2011-08-31
MA30584B1 (fr) 2009-07-01
EP2034999B9 (en) 2011-03-09
US8034377B2 (en) 2011-10-11
EP2034999A2 (en) 2009-03-18
AU2007262958B2 (en) 2011-10-27
WO2007147899A3 (en) 2008-03-13
MY145985A (en) 2012-05-31
DE602007010776D1 (de) 2011-01-05
AR061622A1 (es) 2008-09-10
MX2009000103A (es) 2009-01-23
CA2655570A1 (en) 2007-12-27
KR101380128B1 (ko) 2014-04-11
WO2007147899A2 (en) 2007-12-27
PT2034999E (pt) 2011-01-19
IL195562A0 (en) 2009-09-01
EP2034999B1 (en) 2010-11-24
RU2008152248A (ru) 2010-07-27
TNSN08527A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
CR10507A (es) Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares
CR20150265A (es) Formas de dosificación de ruxolitinib de liberación sostenida
MY177912A (en) Vegf neutralizing prodrugs for the treatment of ocular conditions
IN2012DN06720A (es)
BR112015006029A2 (pt) compostos aza bicíclicos como agonistas de receptor m1 muscarínicos
CY1124473T1 (el) Φυτοσυμπλοκα απο citrus bergamia
DOP2014000170A (es) Compuestos de imidazopirrolidinona
IN2014DN06501A (es)
BR112016011792A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
CO6571913A2 (es) Derivados de fumarato de ácido graso y sus usos
WO2014096425A3 (en) Prodrugs of monomethyl fumarate (mmf)
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
CO6791613A2 (es) Tratamiento de transtornos del espectro autista que utiliza ácido glicil-l-2-metilprolil-l-glutámico
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
UY32944A (es) Compuestos poliméricos de ésteres silil benzoicos, sus usos y composiciones
FR2988103B1 (fr) Production d'acide docosahexaenoique et/ou d'acide eicosapentaenoique et/ou des carotenoide(s) en mode mixotrophe par nitzschia
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
IN2014DN09002A (es)
MX2015017202A (es) Formulacion de liberacion modificada.
ECSP18002561A (es) Sales y profármacos de 1-metil-d-triptófano
CO2020002500A2 (es) Análogos de insulina acilados novedosos y usos de estos
GT200700020A (es) Compuestos y derivados de dibencilamina
Zhong et al. Anti-proliferation and induced mitochondria-mediated apoptosis of ganoderic acid Mk from Ganoderma lucidum mycelia in cervical cancer HeLa cells
BR112013000941A2 (pt) formulações de 14-epi-análogos de vitamina d